Jun 02, 2016 7:35am EDT Intensity Therapeutics Issued First US Patent for Immune-based Cancer Therapeutic Agents
Apr 19, 2016 7:35am EDT Intensity Therapeutics Reports that INT230-6’s Anti-cancer Mechanism is a Combination of Cell Death with Immune System Activation
Mar 08, 2016 7:30am EST Intensity Therapeutics Selected to Present at BioCentury Future Leaders Conference
Mar 03, 2016 7:35am EST Intensity Therapeutics Reports anti-Cancer Immunological Effect Generated by INT230-6
Nov 05, 2015 7:35am EST Intensity Therapeutics Preclinical Results Show Anti-Cancer Synergy of INT230-6 with Anti-PD-1 Compounds
Oct 22, 2015 7:35am EDT Intensity Therapeutics Forms Scientific Advisory Board Comprised of World-Leading Oncologists and Scientists
Apr 16, 2015 7:36am EDT Intensity Therapeutics, Inc.’s Research Selected for Presentation at the 2015 American Association for Cancer Research Annual Meeting
Oct 09, 2014 7:30am EDT Intensity Therapeutics, Inc.’s Research Selected for Presentation at the Annual National Cancer Institute Cancer Immunology and Immunotherapy Conference
Sep 03, 2014 7:36am EDT Intensity Therapeutics, Inc. Appoints Ian B. Walters M.D., MBA as Vice President and Chief Medical Officer
May 28, 2014 7:33am EDT Intensity Therapeutics, Inc. Awarded Cooperative Research and Development Agreement from the National Cancer Institute
